MAPT and Alzheimer disease: To label PHFTau-ir neurons, we chose the antibody PHFTau-AT8 because it is commonly used to classify the neurofibrillary degeneration into stages known as the Braak stages (Braak et al., 2006), and the antibody PHFTau-pS396 because phosphorylation at site S396 is commonly related to late stages of AD (Regalado-Reyes et al., 2019) and it is mostly found in NFTs (Kimura et al., 1996).